Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy
September 16, 2023 at 13:59 PM EDT
Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule inhibitor of USP1 for BRCA-mutated tumors to Exelixis.
